These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 15116055

  • 1. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P.
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [Abstract] [Full Text] [Related]

  • 2. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhoseinie SA, Raisjalal GH, Rahsaz M, Pourgholami A, Sagheb F.
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [Abstract] [Full Text] [Related]

  • 3. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements.
    Fredericks S, Jorga A, MacPhee IA, Reboux S, Shiferaw E, Moreton M, Carter ND, Holt DW, Johnston A.
    Clin Transplant; 2007 Jun; 21(2):252-7. PubMed ID: 17425754
    [Abstract] [Full Text] [Related]

  • 4. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T.
    Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
    [Abstract] [Full Text] [Related]

  • 5. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS.
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [Abstract] [Full Text] [Related]

  • 6. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients.
    Foote CJ, Greer W, Kiberd B, Fraser A, Lawen J, Nashan B, Belitsky P.
    Transplantation; 2007 May 27; 83(10):1380-4. PubMed ID: 17519790
    [Abstract] [Full Text] [Related]

  • 7. MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients.
    Foote CJ, Greer W, Kiberd BA, Fraser A, Lawen J, Nashan B, Belitsky P.
    Transplant Proc; 2006 Nov 27; 38(9):2847-9. PubMed ID: 17112845
    [Abstract] [Full Text] [Related]

  • 8. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A.
    Transplant Proc; 2008 Jun 27; 40(5):1690-5. PubMed ID: 18589174
    [Abstract] [Full Text] [Related]

  • 9. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
    Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG.
    Clin Pharmacol Ther; 2004 Nov 27; 76(5):418-27. PubMed ID: 15536457
    [Abstract] [Full Text] [Related]

  • 10. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
    Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, McDade K, Zhang J, Burckart GJ.
    J Clin Pharmacol; 2004 Feb 27; 44(2):135-40. PubMed ID: 14747421
    [Abstract] [Full Text] [Related]

  • 11. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients.
    Kuzuya T, Kobayashi T, Moriyama N, Nagasaka T, Yokoyama I, Uchida K, Nakao A, Nabeshima T.
    Transplantation; 2003 Sep 15; 76(5):865-8. PubMed ID: 14501869
    [Abstract] [Full Text] [Related]

  • 12. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
    Mendes J, Martinho A, Simoes O, Mota A, Breitenfeld L, Pais L.
    Transplant Proc; 2009 Apr 15; 41(3):840-2. PubMed ID: 19376366
    [Abstract] [Full Text] [Related]

  • 13. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH.
    Clin Exp Pharmacol Physiol; 2006 Nov 15; 33(11):1093-8. PubMed ID: 17042920
    [Abstract] [Full Text] [Related]

  • 14. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
    Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q, Wang W.
    Transplant Proc; 2005 Nov 15; 37(1):178-81. PubMed ID: 15808586
    [Abstract] [Full Text] [Related]

  • 15. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L, Aguilera-García I, Docobo-Pérez F, Alamo-Martínez JM, Pareja-Ciuró F, Nuñez-Roldán A, Gómez-Bravo MA, Bernardos-Rodríguez A.
    Transplant Proc; 2008 Nov 15; 40(9):2949-51. PubMed ID: 19010156
    [Abstract] [Full Text] [Related]

  • 16. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK.
    Transplantation; 2003 Oct 27; 76(8):1233-5. PubMed ID: 14578760
    [Abstract] [Full Text] [Related]

  • 17. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K.
    Pharmacogenet Genomics; 2008 May 27; 18(5):413-23. PubMed ID: 18408564
    [Abstract] [Full Text] [Related]

  • 18. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.
    Wang J, Zeevi A, McCurry K, Schuetz E, Zheng H, Iacono A, McDade K, Zaldonis D, Webber S, Watanabe RM, Burckart GJ.
    Transpl Immunol; 2006 Jan 27; 15(3):235-40. PubMed ID: 16431292
    [Abstract] [Full Text] [Related]

  • 19. Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 beta-hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese.
    Li D, Abudula A, Abulahake M, Zhu AP, Lou YQ, Zhang GL.
    J Clin Pharmacol; 2010 Jul 27; 50(7):775-84. PubMed ID: 20160155
    [Abstract] [Full Text] [Related]

  • 20. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
    Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P.
    Pharmacogenetics; 2004 Mar 27; 14(3):147-54. PubMed ID: 15167702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.